134 related articles for article (PubMed ID: 33333529)
1. Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
Raber M; Buchholz N; Vercesi A; Hendawi NA; Inneo V; Di Paola G; Tessa L; Gazzano G; Viglio A; Hasan IM
Urol Int; 2021; 105(3-4):298-303. PubMed ID: 33333529
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
[TBL] [Abstract][Full Text] [Related]
3. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
[TBL] [Abstract][Full Text] [Related]
4. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
[TBL] [Abstract][Full Text] [Related]
5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
6. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
7. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
8. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
[TBL] [Abstract][Full Text] [Related]
9. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
10. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
[TBL] [Abstract][Full Text] [Related]
11. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Mostafid AH; Porta N; Cresswell J; Griffiths TRL; Kelly JD; Penegar SR; Davenport K; McGrath JS; Campain N; Cooke P; Masood S; Knowles MA; Feber A; Knight A; Catto JWF; Lewis R; Hall E
BJU Int; 2020 Jun; 125(6):817-826. PubMed ID: 32124514
[TBL] [Abstract][Full Text] [Related]
12. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
Ather MH; Aziz S; Sulaiman MN
J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
[TBL] [Abstract][Full Text] [Related]
13. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
14. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
[TBL] [Abstract][Full Text] [Related]
15. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
Zargar H; Aning J; Ischia J; So A; Black P
Nat Rev Urol; 2014 Apr; 11(4):220-30. PubMed ID: 24619373
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
17. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
[TBL] [Abstract][Full Text] [Related]
18. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Riedl C
World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
[TBL] [Abstract][Full Text] [Related]
19. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
20. A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
Batura D; Hashemzehi T; Colemeadow J
Int Urol Nephrol; 2018 Jun; 50(6):1053-1059. PubMed ID: 29611146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
